Nihan Korkmaz

-Led commercial evaluations, strategic insights, and revenue forecasting for major M&A and licensing-in opportunities, including Angelini Pharma’s $4.1B acquisition of Catalyst Pharmaceuticals. -Assessed rare and non-rare disease assets globally, with a focus on CNS, epilepsy, and rare diseases, supporting successful acquisitions and pipeline expansion. -Built business cases, valuation models, and long-/short-term sales forecasts for Europe, the U.S., and global opportunities using market research, clinical data, and confidential information. (Including the temporary R&D project management assignment supporting early-stage pipeline development) -Drove executive decision-making through monthly updates, executive-level presentations, and close alignment with cross-functional teams across BD, R&D, Marketing, Medical, Market Access, and Regulatory. -Led due diligence projects in collaboration with top-tier consultancies

-Delivered market, competitor, and strategic analyses for global and regional pharmaceutical clients, supporting decision-making across multiple therapeutic areas. -Identified market gaps and optimized entry and growth strategies for EU HQ and affiliate teams. -Built patient flow and market potential models to assess opportunities across disease areas in Europe and the U.S. -Used clinical and market data to prioritize indications, evaluate commercial potential, and support portfolio decisions. -Developed go-to-market and launch readiness strategies tailored to specific regions and therapeutic areas. -Partnered with cross-functional and remote teams to drive execution across companies, products, and pipeline assets. -Provided strategic insights to support portfolio management, pipeline prioritization, and business growth.

-Managed all marketing activities for blockbuster oncology and hematology products -Successfully launched new indications for Avastin (CRC) and Xeloda (Gastric Cancer, CLL), achieving 90% customer reach. -Held full budget and P&L responsibility, ensuring financial efficiency and strategic allocation of resources. -Led Product Managers and ensured brand alignment across indications to support effective execution in both pre- and post-launch phases. -Drove physician and public awareness initiatives in oncology and hematology, including the design of an award-winning Xeloda patient support program that improved compliance. -Managed launch readiness and marketing activities for key oncology and hematology products as CEMAI Launch Readiness Coordinator for assets including GA101, SC MabThera, Avastin (Ovarian Cancer), and GBM. -Led marketing training, motivated the sales team, and supervised field force and MSL engagement through cycle meetings and regular field visits. -Supported product approval, reimbursement, and pre-marketing activities for new indications.

Master of Cross-cultural and Sustainable Business Management

Product manager responsible for all marketing activities and budget allocation of the products. •Responsible for the coordination and management of Product Sales team. • Sales representative for 6 months, working on the field visiting both physicians and pharmacies.

Master in International and Sustainable Business Management

Vehbi Koc Honor Roll, Spring 1999 Dean’s Honor Roll, 2001-2002 Dean’s Honor Roll, Fall 2001